Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous lymphoid neoplasm with
variations in gene expression profiles and genetic alterations, which lead to substantial …

Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA)
profiling has become a potential novel strategy for patient management in B-cell lymphoma …

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease and represents
the most common subtype of lymphoma. Although 60–70% of all patients can be cured by …

Diffuse large B cell lymphoma represents the most common type of non-Hodgkin lymphoma.
Although the curability rate is high, around 40% of patients will relapse or exhibit refractory …

Advanced colorectal cancer harbors extensive intratumor heterogeneity shaped by neutral
evolution; however, intratumor heterogeneity in colorectal precancerous lesions has been …

Diffuse large B-cell lymphoma (DLBCL) patients are typically treated with
immunochemotherapy containing rituximab (rituximab, cyclophosphamide …

Although the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and
prednisone regimen (R-CHOP) substantially improved outcomes for patients with diffuse …

Simple Summary Many patients with the aggressive cancer diffuse large B-cell lymphoma
(DLBCL) still respond poorly to treatment and suffer from relapsed or refractory disease. The …

Primary refractory/relapsed diffuse large B-cell lymphoma (rrDLBCL) is an unresolved issue
for DLBCL treatment and new treatments to overcome resistance is required. To explore the …

Background The last 5 years' studies using next-generation sequencing provided evidences
that many types of solid tumors present spatial and temporal genetic heterogeneity and are …